A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
With the improvement of living level, the incidence rates of diabetes, obesity, and
hypertension in China increased quickly, which are 11.6%, 7.1% and 18.8% respectively,
according to the newly investigated data. The clustering of diabetes, obesity, hypertension
and dyslipidemia increases the risk of cardiovascular events for patients. GLP-1 (glucagon
like peptide-1) is a kind of incretin discovered in recent years. It was reported that beside
its hypoglycemic and losing weight effects, activator of GLP-1 receptor could decrease blood
pressure and improve lipid metabolism. Sleeve gastrectomy can improve the level of blood
glucose and serum lipid of type 2 diabetic rats by ameliorate insulin level and insulin
resistance, which may be related with the change of gastrointestinal hormones such as ghrelin
and GLP-1. So, intervention of gastrointestinal tract and gastrointestinal hormone secretion
may be a new therapy for glycolipids disorder and vascular complications. But, it is lack of
evidence-based medicine proof on the relationship between prokinetic drug and glycolipids
metabolism. So, the investigators designed a prospective, randomized, double-blinded, placebo
control study, and try to evaluate the effects of prokinetic drug (Mosapride) on the blood
glucose and serum lipid in type 2 diabetic patients.